A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
Completed
Sanofi
Phase 3
2005-06-01
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death
from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter
(AF/AFL).
To assess that dronedarone is well tolerated in this population.
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
Completed
Sanofi
Phase 3
2001-11-01
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
rhythm after electrical, pharmacological or spontaneous conversion of atrial
fibrillation/atrial flutter (AF/AFL).
To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
AF/AFL recurrence.
To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
Completed
Sanofi
Phase 3
2001-11-01
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus
rhythm after electrical, pharmacological or spontaneous conversion of atrial
fibrillation/atrial flutter (AF/AFL).
To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of
AF/AFL recurrence.
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Completed
Sanofi
Phase 3
2007-06-01
The objective of this study is to compare the efficacy and safety of dronedarone to that of
amiodarone for the treatment of patients with atrial fibrillation.
European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure
Terminated
Sanofi
Phase 3
2002-06-01
The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone
versus placebo in patients with symptomatic congestive heart failure (CHF) and left
ventricular dysfunction (LVD) when added to evidence based treatments for CHF.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
